Last 12 months
Inside the activity.
0 purchase rows · 19 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2020 Filed Jul 16, 2020 00:10 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 2,049 | $66.20 | $135,643.80 |
DisclosureSEC source: 0001127602-20-021587 · form4.xml · nonDerivative · entry 3 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,983,481 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $65.63 to $66.48. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 00:10 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 1,000 | $65.03 | $65,030.00 |
DisclosureSEC source: 0001127602-20-021587 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,985,530 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.58 to $65.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 13, 2020 Filed Jul 16, 2020 00:10 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-20-021587 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:58 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 497 | $64.70 | $32,155.90 |
DisclosureSEC source: 0001127602-20-021495 · form4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 508,132 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.59 to $64.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:58 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,500 | $63.78 | $223,230.00 |
DisclosureSEC source: 0001127602-20-021495 · form4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 508,629 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.38 to $64.24. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:58 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 7,049 | $62.84 | $442,959.16 |
DisclosureSEC source: 0001127602-20-021495 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 512,129 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.37 to $63.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 10, 2020 Filed Jul 14, 2020 20:58 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,235 | $64.61 | $596,627.18 |
DisclosureSEC source: 0001127602-20-021495 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,167,304 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. F2 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 09, 2020 Filed Jul 10, 2020 20:05 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $62.04 | $620,400.00 |
DisclosureSEC source: 0001127602-20-021332 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,854,880 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on May 21, 2020. F4 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · derivative · entry 17 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,790 Underlying: Common Stock · 10,000 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $20.93 | $0.00 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · derivative · entry 16 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,195 Underlying: Common Stock · 10,000 shares Expires 2029-03-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 1,143 | $62.16 | $71,048.88 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 12 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $61.94 to $62.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 15,619 | $61.35 | $958,225.65 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 11 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,143 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.80 to $61.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 3,238 | $60.27 | $195,154.26 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 10 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,762 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.77 to $60.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $19.15 | $191,500.00 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 9 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 10,000 | $20.93 | $209,300.00 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 8 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 08, 2020 Filed Jul 10, 2020 20:05 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-20-021332 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,713,858 F1 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2020. F2 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,631 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · derivative · entry 15 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,790 Underlying: Common Stock · 15,631 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,121 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · derivative · entry 14 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,421 Underlying: Common Stock · 24,121 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 22,936 | $0.00 Strike: $12.21 | $0.00 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · derivative · entry 13 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,824 Underlying: Common Stock · 22,936 shares Expires 2027-10-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F10 · derivative.exercise_date: 229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 13,769 | $60.98 | $839,633.62 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $60.63 to $61.39. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 7,739 | $60.05 | $464,726.95 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,769 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.61 to $60.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 17,393 | $58.97 | $1,025,665.21 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,508 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.58 to $59.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 23,787 | $58.21 | $1,384,641.27 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,901 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.57 to $58.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 15,631 | $19.15 | $299,333.65 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,688 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 24,121 | $19.15 | $461,917.15 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 07, 2020 Filed Jul 10, 2020 01:46 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 22,936 | $12.21 | $280,048.56 |
DisclosureSEC source: 0000899243-20-018893 · doc4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,936 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 01:48 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000899243-20-018775 · doc4.xml · derivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 897,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 01:48 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 10,000 | $58.48 | $584,800.00 |
DisclosureSEC source: 0000899243-20-018775 · doc4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,976,540 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 01:48 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0000899243-20-018775 · doc4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 01:52 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 100 | $60.59 | $6,059.00 |
DisclosureSEC source: 0000899243-20-018777 · doc4.xml · nonDerivative · entry 5 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 519,178 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F5 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 01:52 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 6,894 | $59.91 | $413,019.54 |
DisclosureSEC source: 0000899243-20-018777 · doc4.xml · nonDerivative · entry 4 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 519,278 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $59.46 to $60.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 01:52 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 3,052 | $59.19 | $180,647.88 |
DisclosureSEC source: 0000899243-20-018777 · doc4.xml · nonDerivative · entry 3 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 526,172 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $58.45 to $59.45. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 06, 2020 Filed Jul 9, 2020 01:52 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 1,000 | $57.85 | $57,850.00 |
DisclosureSEC source: 0000899243-20-018777 · doc4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 529,224 F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $57.39 to $58.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · ownership.nature: These shares are owned directly by a trust for the benefit of Mr. Bancel's children and of which the trustee is an independent institution. The reporting person disclaims Section 16 beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 06, 2020 Filed Jan 11, 2021 21:14 UTC |
Meline David WChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 271,303 | $0.00 Strike: $59.15 | $0.00 |
DisclosureSEC source: 0001127602-21-001413 · form4.xml · derivative · entry 1 Meline David W · CIK 0001444612 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,303 Underlying: Common Stock · 271,303 shares Expires 2030-07-06 F1 · derivative.exercise_date: 25% of this option will vest and become exercisable on July 6, 2021 with the remainder vesting in 12 equal quarterly installments thereafter. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 21:23 UTC |
Hoge StephenPresident
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001127602-20-021211 · form4.xml · derivative · entry 4 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907,431 Underlying: Common Stock · 10,000 shares Expires 2023-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 21:23 UTC |
Hoge StephenPresident
|
SaleCommon Stock | 10,000 | $59.94 | $599,400.00 |
DisclosureSEC source: 0001127602-20-021211 · form4.xml · nonDerivative · entry 2 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,976,540 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 21:23 UTC |
Hoge StephenPresident
|
Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0001127602-20-021211 · form4.xml · nonDerivative · entry 1 Hoge Stephen · CIK 0001760669 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,986,540 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 27, 2018, as amended on June 1, 2020. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:17 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 10,000 | $59.94 | $599,400.00 |
DisclosureSEC source: 0001127602-20-021168 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 7,864,880 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on 12/18/2018, and amended on May 21, 2020. F2 · ownership.nature: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:48 UTC |
Tallett Elizabeth EDirector
|
GrantStock Option (Right to Buy) · Derivative | 11,229 | $61.59 Strike: $61.59 | $691,594.11 |
DisclosureSEC source: 0001127602-20-020955 · form4.xml · derivative · entry 2 Tallett Elizabeth E · CIK 0001192460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,229 Underlying: Common Stock · 11,229 shares Expires 2030-07-01 F2 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:48 UTC |
Tallett Elizabeth EDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,590 | $61.59 Strike: $61.59 | $775,418.10 |
DisclosureSEC source: 0001127602-20-020955 · form4.xml · derivative · entry 1 Tallett Elizabeth E · CIK 0001192460 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,590 Underlying: Common Stock · 12,590 shares Expires 2030-07-01 F1 · derivative.exercise_date: This option will be fully vested and exercisable on July 1, 2021. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:18 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,344 | $62.92 | $587,924.48 |
DisclosureSEC source: 0001127602-20-020892 · form4.xml · nonDerivative · entry 2 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 9,176,539 F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 18, 2018, as amended on September 16, 2019. F3 · ownership.nature: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose. Read SEC document |
| July 01, 2020 Filed Jul 2, 2020 20:18 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
SaleCommon Stock | 9,000 | $62.92 | $566,280.00 |
DisclosureSEC source: 0001127602-20-020892 · form4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,715,858 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as amended on May 21, 2020. Read SEC document |
| July 01, 2020 Filed Jul 9, 2020 01:52 UTC |
Bancel StephaneDirector · Chief Executive Officer
|
GiftCommon Stock | 1,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-018777 · doc4.xml · nonDerivative · entry 1 Bancel Stephane · CIK 0001443340 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,714,858 F1 · kind: The reported disposition was effected pursuant to a Rule 10b5-1 trading plan adopted on September 16, 2019, as amended on May 21, 2020. F2 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:10 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 15,631 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-020885 · form4.xml · derivative · entry 7 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,542 Underlying: Common Stock · 15,631 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:10 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,121 | $0.00 Strike: $19.15 | $0.00 |
DisclosureSEC source: 0001127602-20-020885 · form4.xml · derivative · entry 6 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,173 Underlying: Common Stock · 24,121 shares Expires 2026-08-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F5 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:10 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 21,385 | $64.57 | $1,380,829.45 |
DisclosureSEC source: 0001127602-20-020885 · form4.xml · nonDerivative · entry 5 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $64.13 to $65.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:10 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 12,967 | $63.56 | $824,182.52 |
DisclosureSEC source: 0001127602-20-020885 · form4.xml · nonDerivative · entry 4 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,385 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $63.12 to $64.12. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:10 UTC |
Zaks Tal ZviChief Medical Officer
|
SaleCommon Stock | 5,400 | $62.83 | $339,282.00 |
DisclosureSEC source: 0001127602-20-020885 · form4.xml · nonDerivative · entry 3 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,352 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $62.11 to $63.11. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:10 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 15,631 | $19.15 | $299,333.65 |
DisclosureSEC source: 0001127602-20-020885 · form4.xml · nonDerivative · entry 2 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
| June 30, 2020 Filed Jul 2, 2020 20:10 UTC |
Zaks Tal ZviChief Medical Officer
|
Exercise / conversionCommon Stock | 24,121 | $19.15 | $461,917.15 |
DisclosureSEC source: 0001127602-20-020885 · form4.xml · nonDerivative · entry 1 Zaks Tal Zvi · CIK 0001690927 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,121 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.